Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 801640, 8 pages
http://dx.doi.org/10.1155/2014/801640
Research Article

BMP-4 Genetic Variants and Protein Expression Are Associated with Platinum-Based Chemotherapy Response and Prognosis in NSCLC

1Department of Oncology, Third Affiliated Hospital of Harbin Medical University, 150 Ha Ping Road, Nangang District, Harbin, Heilongjiang Province 150086, China
2Department of Cardiac Surgery, Second Affiliated Hospital of Harbin Medical University, 246 Xue Fu Road, Nangang District, Harbin, Heilongjiang Province 150086, China
3Department of Pathology, The Third Affiliated Hospital of Harbin Medical University, 246 Haping Road, Nangang District, Harbin, Heilongjiang Province 150081, China
4Laboratory of Medical Genetics, Harbin Medical University, 194 Xue Fu Road, Nangang District, Harbin, Heilongjiang Province 150086, China

Received 26 August 2013; Revised 12 November 2013; Accepted 13 November 2013; Published 19 March 2014

Academic Editor: Maria Lina Tornesello

Copyright © 2014 Sun Xian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Tsim, C. A. O'Dowd, R. Milroy, and S. Davidson, “Staging of non-small cell lung cancer (NSCLC): a review,” Respiratory Medicine, vol. 104, no. 12, pp. 1767–1774, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Kosmidis, “Chemotherapy in NSCLC: historical review,” Lung Cancer, vol. 38, supplement 3, pp. S19–S22, 2002. View at Google Scholar · View at Scopus
  3. M. A. Hildebrandt, J. Gu, and X. Wu, “Pharmacogenomics of platinum-based chemotherapy in NSCLC,” Expert Opinion on Drug Metabolism and Toxicology, vol. 5, no. 7, pp. 745–755, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Chang, “Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC,” Lung Cancer, vol. 71, no. 1, pp. 3–10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. M. D. Brundage, D. Davies, and W. J. Mackillop, “Prognostic factors in non-small cell lung cancer: a decade of progress,” Chest, vol. 122, no. 3, pp. 1037–1057, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. J. L. Johnson, S. Pillai, and S. P. Chellappan, “Genetic and biochemical alterations in non-small cell lung cancer,” Biochemistry Research International, vol. 2012, Article ID 940405, 18 pages, 2012. View at Publisher · View at Google Scholar
  7. G. Metro and L. Crino, “Novel molecular trends in the management of advanced non-small-cell lung cancer,” Expert Review of Anticancer Therapy, vol. 12, no. 6, pp. 729–732, 2012. View at Publisher · View at Google Scholar
  8. A. A. Dmitriev, V. I. Kashuba, K. Haraldson et al., “Genetic and epigenetic analysis of non-small cell lung cancer with NotI-microarrays,” Epigenetics, vol. 7, no. 5, pp. 502–513, 2012. View at Google Scholar · View at Scopus
  9. X. W. Hou, L. F. Wang, N. Wang et al., “The G501C polymorphism of oxidized LDL receptor gene [OLR-1] is associated with susceptibility and serum C-reactive protein concentration in Chinese essential hypertensives,” Clinica Chimica Acta, vol. 388, no. 1-2, pp. 200–203, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Li, Z. Sun, J. M. Cunningham et al., “Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy,” Clinical Cancer Research, vol. 17, no. 11, pp. 3830–3840, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Jiang, Z. Z. Zhu, F. Liu et al., “STAT3 gene polymorphisms and susceptibility to non-small cell lung cancer,” Genetics and Molecular Research, vol. 10, no. 3, pp. 1856–1865, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. M. F. Zheng, Y. Ji, X. B. Wu, S. G. Ye, and J. Y. Chen, “EphB4 gene polymorphism and protein expression in non-small-cell lung cancer,” Molecular Medicine Reports, vol. 6, no. 2, pp. 405–408, 2012. View at Google Scholar
  13. C. Xu, X. Wang, Y. Zhang, and L. Li, “Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer,” Chinese Journal of Lung Cancer, vol. 14, no. 12, pp. 912–917, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. X. Hou, N. Appleby, T. Fuentes et al., “Isolation, characterization, and spatial distribution of cardiac progenitor cells in the sheep heart,” Journal of Clinical & Experimental Cardiology, p. S6, 2012. View at Google Scholar
  15. B. L. Hogan, “Bone morphogenetic proteins: multifunctional regulators of vertebrate development,” Genes and Development, vol. 10, no. 13, pp. 1580–1594, 1996. View at Google Scholar · View at Scopus
  16. S. F. Chang, T. K. Chang, H. H. Peng et al., “BMP-4 induction of arrest and differentiation of osteoblast-like cells via p21CIP1 and p27KIP1 regulation,” Molecular Endocrinology, vol. 23, no. 11, pp. 1827–1838, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Wang, X. Hou, and Y. Li, “Association between transforming growth factor 1 polymorphisms and atrial fibrillation in essential hypertensive subjects,” Journal of Biomedical Science, vol. 17, no. 1, p. 23, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Y. Xu, X. W. Hou, L. F. Wang, N. F. Wang, and J. Xu, “Association between transforming growth factor β1 polymorphisms and left ventricle hypertrophy in essential hypertensive subjects,” Molecular and Cellular Biochemistry, vol. 335, no. 1-2, pp. 13–17, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Ivanova, H. Zouridis, Y. Wu et al., “Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer,” Gut, vol. 62, no. 1, pp. 22–33, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Y. Lin, Y. J. Chen, Y. L. Huang et al., “Association of bone morphogenetic protein 4 gene polymorphisms with nonsyndromic cleft lip with or without cleft palate in Chinese children,” DNA and Cell Biology, vol. 27, no. 11, pp. 601–605, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. X. Wang, E. Cui, H. Zeng et al., “RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC,” PLoS One, vol. 7, no. 10, Article ID e43734, 2012. View at Google Scholar
  22. A. Santo, G. Genestreti, A. Terzi et al., “Gemcitabine (GEM) and Vindesine (VDS) in advanced non-small cell lung cancer (NSCLC): a phase II study in elderly or poor performance status patients,” Lung Cancer, vol. 53, no. 3, pp. 355–360, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Niho, K. Kubota, K. Goto et al., “First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study,” Journal of Clinical Oncology, vol. 24, no. 1, pp. 64–69, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Soini, K. Kahlos, A. Puhakka et al., “Expression of inducible nitric oxide synthase in healthy pleura and in malignant mesothelioma,” British Journal of Cancer, vol. 83, no. 7, pp. 880–886, 2000. View at Google Scholar · View at Scopus
  25. J. H. Lee, J. Pyon, S. H. Lee et al., “Greater expression of TC21/R-ras2 in highly aggressive malignant skin cancer,” International Journal of Dermatology, vol. 50, no. 8, pp. 956–960, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. L. M. Reis, R. C. Tyler, K. F. Schilter et al., “BMP4 loss-of-function mutations in developmental eye disorders including SHORT syndrome,” Human Genetics, vol. 130, no. 4, pp. 495–504, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Ramesh Babu, S. G. Wilson, I. M. Dick, F. M. A. Islam, A. Devine, and R. L. Prince, “Bone mass effects of a BMP4 gene polymorphism in postmenopausal women,” Bone, vol. 36, no. 3, pp. 555–561, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Capasso, F. Ayala, R. Russo, R. A. Avvisati, R. Asci, and A. Iolascon, “A predicted functional single-nucleotide polymorphism of bone morphogenetic protein-4 gene affects mRNA expression and shows a significant association with cutaneous melanoma in Southern Italian population,” Journal of Cancer Research and Clinical Oncology, vol. 135, no. 12, pp. 1799–1807, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Lombardo, A. Scopelliti, P. Cammareri et al., “Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice,” Gastroenterology, vol. 140, no. 1, pp. 297–309, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. N. J. Wood, “Cancer: integrated epigenomic analysis sheds light on role of BMP4 in regulating cisplatin sensitivity in gastric cancer,” Nature Reviews Gastroenterology and Hepatology, vol. 9, no. 6, p. 301, 2012. View at Publisher · View at Google Scholar
  31. L. Laatio, P. Myllynen, R. Serpi et al., “BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cells,” Tumor Biology, vol. 32, no. 5, pp. 985–995, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. X. Guo, L. Xiong, L. Zou, and J. Zhao, “Upregulation of bone morphogenetic protein 4 is associated with poor prognosis in patients with hepatocellular carcinoma,” Pathology and Oncology Research, vol. 18, no. 3, pp. 635–640, 2012. View at Publisher · View at Google Scholar · View at Scopus